medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2012, Number 1

<< Back Next >>

Residente 2012; 7 (1)

Aspectos básicos sobre trombofilia, inflamación y autoinmunidad

Rubio JB, Salazar PM, Nava A

Language: Spanish
References: 40
Page: 16-20
PDF size: 39.85 Kb.


ABSTRACT

Maintenance of normal blood flow requires an equilibrium between procoagulant and anticoagulant factors, occasionally procoagulant activity predominates, leading to clots formation; frequently, tissue damage is the triggering factor. Hereditary factors, primary or acquired play a role in the development of thrombosis. Primary thrombophilia is associated to hereditary factors, which promote hypercoagulability because natural anticoagulants are not exerting their activity. On the other hand, acquired thrombophilia may occur associated to autoimmune diseases, cancer, surgical procedures, pregnancy, postpartum period, and obesity. Activation of the coagulation system is characterized by the coparticipation of inflammatory response components, factors related to the subjacent disease, and other procoagulant factors. The study of patients with thrombosis should include both inflammatory and autoimmune response markers.


REFERENCES

  1. Williamson D, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 –› Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-1144.

  2. Gutiérrez-Tous MR. Trombofilia, ¿cuándo, qué pruebas y a quién? Sem Fund Esp Reumatol 2005; 6: 133-143.

  3. De Stefano V, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87: 1095-1108.

  4. 4 Rubio-Jurado B, Salazar Páramo M, Medrano Muñoz F, González-Ojeda A, Arnulfo-Nava. Trombofilia, autoinmunidad y tromboprofilaxis postoperatoria. Cir Ciruj 2007; 75: 313-323.

  5. Tofler GH, Levy D, Mittleman M, Sutherland P, Lipinska I, Muller JE, D’Agostino RB. Relation of the prothrombotic state to increasing age (from the Framingham offspring study). Am J Cardiol 2005; 96: 1280-1283.

  6. Hertzberg M. Genetic testing for thrombophilia mutations. Sem Thromb Hemost 2005; 31: 33-38.

  7. Mannuccio MP. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98: 21-22.

  8. Carrillo ER, Carvajal RR, Contreras DV, Hernández AC. Rompiendo un paradigma: del modelo humoral al modelo celular de la coagulación. Su aplicación clínica en el enfermo grave. Med Crit Terapia Int 2004; 18(1): 17-23.

  9. Mackman N. Role of tissue factor in hemostasis, thrombosis and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.

  10. Ruggeri ZM. Platelets in atherothrombosis. Nature Medicine 2002; 8(11): 1227-1234.

  11. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005; 257: 209-223.

  12. 12 Orfeo T, Brummel-Ziedins KE, Man K. The tissue factor requirement in blood coagulation. J Biol Chem 2005; 280: 42887-42896.

  13. Bombeli T. Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. Br J Anaesth 2004; 93: 275-287.

  14. Mangiafico R, Sarnataro F, Mangiafico M, Fiore CE. Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age and Ageing 2006; 35: 60-65.

  15. Sepulveda JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol 2005; 20(5): 407-416.

  16. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa D, Kurosawa S. Inflammation, sepsis, and coagulation. Haematologica 1999; 84: 254-259.

  17. Urbanus RT, Derksen R, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Reviews 2008; 22: 93-105.

  18. Crocea K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.

  19. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.

  20. Von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.

  21. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451(21): 914-918.

  22. Levi M, Nieuwdorp M, van der Poll T, Stroes, E. Metabolic modulation of inflammation-induced activation of coagulation. Sem Thromb Hemost 2008; 43(1): 26-32.

  23. Liuzzo G, Giubilato G, Pinnelli M. T cells and cytokines in atherogenesis. Lupus 2005; 14: 732-735.

  24. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25: 1776-1785.

  25. Hansson GK. The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 2006; 6: 508-519.

  26. Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121(6): 458-463.

  27. Perry DJ. Antithrombin and its inherited deficiencies. Blood Reviews 1994; 8(1): 37-55.

  28. Crocea K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.

  29. Vlagea AD, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, Pascual-Salcedo D. Antiphosphatidylserine/Prothrombin Antibodies (aPS/PT) as Potential Markers of Antiphospholipid Syndrome. Clin Appl Thromb Hemost. 2012 Mar 2. [Epub ahead of print] PubMed PMID: 22387581.

  30. De Groot PG. Pathophysiology of antiphospholipid antibodies. Neth J Med 2004; 62(8): 267-272.

  31. Bas de Laat H, Urbanus RT, Roest M, de Groot PG. b2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-3602.

  32. Ortel TL. The syndrome antiphospholipid: What are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 2006; 21: 79-83.

  33. Giannakopoulos B, Passam F, Rahgoza S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-430.

  34. Urbanus RT, Derksen R, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Reviews 2008, 22: 93-105.

  35. De Groot PG, Derksenp R. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2007; 3: 1854-1860.

  36. Pierangeli S, Chen PP, González EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13: 366-375.

  37. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MA, Palomo I, Harris N, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-250.

  38. Nojima J, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematous. Hematologica 2006; 91: 699-702.

  39. Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, Nakamura M, Nobori T, Nakano T. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. American Journal of Hematology 2004; 76: 338-342.

  40. Oku K, Atsumi T, Amengual O, Koike T. Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost 2008; 34: 335-339.




2020     |     www.medigraphic.com